|
1
|
Borkowska J, Schwartz RA, Kotulska K and
Jozwiak S: Tuberous sclerosis complex: tumors and tumorigenesis.
Int J Dermatol. 50:13–20. 2011. View Article : Google Scholar
|
|
2
|
Osborne JP, Fryer A and Webb D:
Epidemiology of tuberous sclerosis. Ann NY Acad Sci. 615:125–127.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crino PB, Nathanson KL and Henske EP: The
tuberous sclerosis complex. N Engl J Med. 355:1345–1356. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Benyounes N, Fohlen M, Devys JM, et al:
Cardiac rhabdomyomas in tuberous sclerosis patients: a case report
and review of the literature. Arch Cardiovasc Dis. 105:442–445.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hunter AG, Nezarati MM and Velsher L:
Absence of signs of systemic involvement in four patients with
bilateral multiple facial angiofibromas. Am J Med Genet A.
152A:657–664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sterman H, Furlan AB, Matushita H and
Teixeira MJ: Subependymal giant cell astrocytoma associated with
tuberous sclerosis presenting with intratumoral bleeding. Case
report and review of literature. Childs Nerv Syst. 29:335–339.
2013. View Article : Google Scholar
|
|
7
|
Meraj R, Wikenheiser-Brokamp KA, Young LR
and McCormack FX: Lymphangioleiomyomatosis: new concepts in
pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med.
33:486–497. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crino PB: Evolving neurobiology of
tuberous sclerosis complex. Acta Neuropathol. 125:317–332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Franz DN and Weiss BD: Molecular therapies
for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci
Rep. 12:294–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davies DM, Johnson SR, Tattersfield AE, et
al: Sirolimus therapy in tuberous sclerosis or sporadic
lymphangioleiomyomatosis. N Engl J Med. 358:200–203. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Curatolo P and Moavero R: mTOR inhibitors
in tuberous sclerosis complex. Curr Neuropharmacol. 10:404–415.
2012. View Article : Google Scholar :
|
|
12
|
Franz DN: Everolimus in the treatment of
subependymal giant cell astrocytomas, angiomyolipomas, and
pulmonary and skin lesions associated with tuberous sclerosis
complex. Biologics. 7:211–221. 2013.PubMed/NCBI
|
|
13
|
Pressey JG, Wright JM, Geller JI, et al:
Sirolimus therapy for fibromatosis and multifocal renal cell
carcinoma in a child with tuberous sclerosis complex. Pediatr Blood
Cancer. 54:1035–1037. 2010.PubMed/NCBI
|
|
14
|
Lam C, Bouffet E, Tabori U, et al:
Rapamycin (sirolimus) in tuberous sclerosis associated pediatric
central nervous system tumors. Pediatr Blood Cancer. 54:476–479.
2010. View Article : Google Scholar
|
|
15
|
Hofbauer GF, Marcollo-Pini A, Corsenca A,
et al: The mTOR inhibitor rapamycin significantly improves facial
angiofibroma lesions in a patient with tuberous sclerosis. Br J
Dermatol. 159:473–475. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Franz DN, Leonard J, Tudor C, et al:
Rapamycin causes regression of astrocytomas in tuberous sclerosis
complex. Ann Neurol. 59:490–498. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Birca A, Mercier C and Major P: Rapamycin
as an alternative to surgical treatment of subependymal giant cell
astrocytomas in a patient with tuberous sclerosis complex. J
Neurosurg Pediatr. 6:381–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Staehler M, Sauter M, Helck A, et al:
Nephron-sparing resection of angiomyolipoma after sirolimus
pretreatment in patients with tuberous sclerosis. Int Urol Nephrol.
44:1657–1661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sparagana SP, Wilkes DC, Thompson CE and
Bowers DC: Optic nerve tumor in tuberous sclerosis complex is not
responsive to sirolimus. Pediatr Neurol. 42:443–446. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. PLoS Med. 6:e10000972009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higgins JPT and Green S: Cochrane Handbook
for Systematic Reviews of Interventions Version 5.10. The Cochrane
Collaboration; Oxford: 2011
|
|
23
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ades AE, Lu G and Higgins JP: The
interpretation of random-effects meta-analysis in decision models.
Med Decis Making. 25:646–654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Franz DN, Belousova E, Sparagana S, et al:
Efficacy and safety of everolimus for subependymal giant cell
astrocytomas associated with tuberous sclerosis complex (EXIST-1):
a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet. 381:125–132. 2013. View Article : Google Scholar
|
|
26
|
Foster RS, Bint LJ and Halbert AR: Topical
0.1% rapamycin for angiofibromas in paediatric patients with
tuberous sclerosis: a pilot study of four patients. Australas J
Dermatol. 53:52–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Salido R, Garnacho-Saucedo G,
Cuevas-Asencio I, et al: Sustained clinical effectiveness and
favorable safety profile of topical sirolimus for tuberous
sclerosis - associated facial angiofibroma. J Eur Acad Dermatol
Venereol. 26:1315–1318. 2012. View Article : Google Scholar
|
|
28
|
Wataya-Kaneda M, Tanaka M, Nakamura A,
Matsumoto S and Katayama I: A topical combination of rapamycin and
tacrolimus for the treatment of angiofibroma due to tuberous
sclerosis complex (TSC): a pilot study of nine Japanese patients
with TSC of different disease severity. Br J Dermatol. 165:912–916.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ehninger D: From genes to cognition in
tuberous sclerosis: implications for mTOR inhibitor-based treatment
approaches. Neuropharmacology. 68:97–105. 2013. View Article : Google Scholar
|
|
30
|
Han JM and Sahin M: TSC1/TSC2 signaling in
the CNS. FEBS Lett. 585:973–980. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang H, Wang X, Zhang Y, et al: Modulation
of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
J Cell Physiol. 229:17–26. 2014.
|
|
32
|
Guo Y and Kwiatkowski DJ: Equivalent
benefit of rapamycin and a potent mTOR ATP-competitive inhibitor,
MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol
Cancer Res. 11:467–473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cambiaghi M, Cursi M, Magri L, et al:
Behavioural and EEG effects of chronic rapamycin treatment in a
mouse model of tuberous sclerosis complex. Neuropharmacology.
67:1–7. 2013. View Article : Google Scholar
|
|
34
|
Zhang Y and Zheng XF: mTOR-independent
4E-BP1 phosphorylation is associated with cancer resistance to mTOR
kinase inhibitors. Cell Cycle. 11:594–603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guba M, Yezhelyev M, Eichhorn ME, et al:
Rapamycin induces tumor-specific thrombosis via tissue factor in
the presence of VEGF. Blood. 105:4463–4469. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Frost P, Berlanger E, Mysore V, et al:
Mammalian target of rapamycin inhibitors induce tumor cell
apoptosis in vivo primarily by inhibiting VEGF expression and
angiogenesis. J Oncol. 2013:8970252013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roa J, Garcia-Galiano D, Castellano JM, et
al: Metabolic control of puberty onset: new players, new
mechanisms. Mol Cell Endocrinol. 324:87–94. 2010. View Article : Google Scholar
|
